Valuation: Standard BioTools Inc.

Market Cap 242M 217M 201M 182M 339M 23.04B 344M 2.4B 955M 12.05B 908M 888M 38.27B P/E 2026 *
-6.16x
P/E 2027 * -3.85x
Enterprise Value 242M 217M 201M 182M 339M 23.04B 344M 2.4B 955M 12.05B 908M 888M 38.27B EV / Sales 2026 *
2.93x
EV / Sales 2027 * 2.95x
Free-Float
93.76%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Standard BioTools Inc.

1 day+0.15%
1 week-5.08%
Current month-16.69%
1 month-15.17%
3 months-22.36%
6 months-33.11%
Current year-51.80%
1 week 0.59
Extreme 0.5881
0.67
1 month 0.59
Extreme 0.5881
0.8
Current year 0.59
Extreme 0.5881
1.67
1 year 0.59
Extreme 0.5881
1.72
3 years 0.59
Extreme 0.5881
3.04
5 years 0.59
Extreme 0.5881
5.26
10 years 0.59
Extreme 0.5881
14.9
Manager TitleAgeSince
Director of Finance/CFO 55 01/09/2024
Chief Executive Officer 63 01/10/2021
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 72 01/04/2022
Director/Board Member 53 04/04/2022
Director/Board Member 63 01/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Tax

Founder

-28,195 0.0072%
20/08/26 Tax

Executive/Senior Manager

-25,729 0.0066%
20/08/26 Tax

Chief Executive Officer

-97,627 0.0249%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%-5.08%-51.42%-68.03% 242M
+1.61%+1.46%+26.28%+62.21% 256B
+0.89%+0.09%+7.92%+26.46% 163B
-0.38%+3.75%-18.56%+71.84% 155B
-5.84%-4.67%-57.98%-15.22% 65.3B
+1.06%+3.82%+11.67%+47.18% 52.35B
+1.72%+2.78%-13.92%-7.13% 51.93B
+1.39%-0.85%+9.09%+67.03% 50.75B
+2.25%+2.10%+24.43%+79.38% 50.04B
+1.78%+4.24%+37.85%+101.47% 46.03B
Average +0.40%+1.23%-2.47%+36.52% 89.07B
Weighted average by Cap. +0.75%+1.68%+5.25%+49.96%

Financials

2026 *2027 *
Net sales 82.5M 74.02M 68.43M 61.98M 116M 7.86B 117M 818M 326M 4.11B 310M 303M 13.05B 82.1M 73.66M 68.1M 61.68M 115M 7.82B 117M 814M 324M 4.09B 308M 302M 12.99B
Net income -38.8M -34.81M -32.18M -29.15M -54.46M -3.7B -55.12M -385M -153M -1.93B -146M -143M -6.14B -62.9M -56.43M -52.18M -47.25M -88.28M -5.99B -89.35M -624M -248M -3.13B -236M -231M -9.95B
Net Debt - -
Projected Income Statement - Annual - Standard BioTools Inc.
Logo Standard BioTools Inc.
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Employees
387
Date Price Change Volume
29/10/26 $0.6170 +0.15% 741,692
27/10/26 $0.6161 +2.68% 1,036,952
26/10/26 $0.6000 -0.92% 644,199
23/10/26 $0.6056 -4.72% 852,999
22/10/26 $0.6356 -2.22% 1,201,653
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Standard BioTools Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.6161USD
Average target price
1.350USD
Spread / Average Target
+119.12%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Standard BioTools Inc.